Buyers used to skip past the insurance section of a cannabis diligence file. Cannabis M&A doesn't work that way anymore, and sellers who haven't fixed their insurance structure are about to find out the hard way.
The 280E Liability Overhang Every Advisor Already Knows
Cannabis M&A advisors are already fluent in 280E exposure as a diligence item. Major multi-state operators carry contested 280E liabilities (assessed or accrued, formally disputed, and disclosed as an outstanding exposure — not yet finally decided or paid) in the hundreds of millions: Trulieve at $696 million [5], Curaleaf at $531.5 million, Verano at $378.3 million, and Cresco at $171.4 million, nearly $1.8 billion combined across just these four, as disclosed in company financial statements and investor filings. That number is already priced into deal models across the industry.
Insurance structure is the next line item catching up to that level of scrutiny. If tax exposure is already a modeled variable, the cost structure and balance sheet impact of how a target insures itself is a logical next place for buyers to look, and it's a place most targets haven't cleaned up yet.
What Acquirers Are Starting to Ask
Standard cannabis policies come from a constrained surplus lines market, priced expensively and often thin on regulatory defense and business interruption coverage. That combination is now a diligence flag: what exactly is excluded, what does the loss history actually show, and is the seller sitting on structural risk the buyer would inherit on day one.
A captive with funded reserves and a clean multi-year claims history is a demonstrable asset in a deal. It's real reserves on the balance sheet, it's evidence of disciplined risk management, and it removes the open question of whether a commercial policy lapses or a carrier exits mid-transaction. The reverse is also true: a captive that's underfunded, poorly governed, or out of compliance with its domicile's requirements is a liability an acquirer has to unwind or absorb, and it can depress or complicate a valuation just as easily as a clean one supports it.
Most targets, though, simply have no captive at all, and that's not itself a red flag. It just means the buyer is inheriting full exposure to the commercial market's pricing and exclusions on day one, with no reserves already accumulated. For a buyer, that's less a diligence problem than a value-creation opportunity: forming a captive post-close is one of the more straightforward ways to improve a newly acquired operation's cost structure, provided the deal team actually models that opportunity rather than assuming the target's current insurance spend is fixed.
The Rescheduling Wildcard M&A Advisors Need to Track
Medical-only cannabis businesses received a partial 280E reprieve through the April 2026 DOJ order moving state-licensed medical cannabis to Schedule III. That changes the tax-adjusted cash flow picture for that portion of a target's business, an assumption every deal model built before April needs to revisit.
Adult-use cannabis remains Schedule I. The DEA's broader hearing on rescheduling concluded July 15, 2026, with no ruling timeline announced by either the presiding judge or the DEA Administrator. Deal models that assume a near-term "fall ruling" are pricing in a fact that doesn't exist yet. That cuts both ways: a buyer can overpay for an assumed relief timeline that doesn't materialize, or a seller can be underpriced against an outcome that eventually does.
What This Means for How You Structure a Deal
- For diligence teams: make insurance structure a standard line item, not an afterthought. Pull loss runs, current policy exclusions, and whether the target has, or should have, a captive.
- For sellers: getting captive-funded reserves and a clean claims history in place before a sale process starts is a valuation lever, not just a cost-saving move made for its own sake.
- For buyers: model the target's insurance line as two separate numbers, not one. Because premiums are non-deductible under 280E, every dollar of premium tied to adult-use revenue costs more in real terms than the invoice shows. For revenue that now sits under the target's state medical license, that penalty partially lifted in April 2026. A deal model that applies one blended discount to the whole insurance line is already wrong.
Contact 3F Captive Services for a no-cost policy analysis on a target or portfolio company. We identify the coverage gaps and captive readiness that belong in your diligence file.
⚠ This post is for informational purposes only and does not constitute insurance, legal, tax, or investment advice. Deal-specific facts, valuation methods, and regulatory status vary. Consult qualified legal, tax, and insurance advisors regarding any specific transaction.
Sources
[1] Company financial statements and investor disclosures (Trulieve, Curaleaf, Verano, Cresco), as compiled in 3F Captive Services research materials.
[2] Marijuana Moment. "Feds Announce Marijuana Industry Tax Guidance Is Coming As Rescheduling Takes Effect." April 23, 2026. https://www.marijuanamoment.net/feds-announce-marijuana-industry-tax-guidance-is-coming-as-rescheduling-takes-effect/
[3] Marijuana Moment. "Federal Marijuana Rescheduling Hearing Wraps Up, With DEA Judge Laying Out Next Steps." July 16, 2026. https://www.marijuanamoment.net/federal-marijuana-rescheduling-hearing-wraps-up-with-dea-judge-laying-out-next-steps/
[4] Internal Revenue Code § 280E, 26 U.S.C. § 280E.
[5] MJBizDaily. "'Reckless' 280E Gamble Backfires as Feds Demand Millions From Cannabis MSO." May 20, 2026 (citing Trulieve Cannabis Corp. Q1 2026 quarterly filing, $696 million in uncertain tax liabilities as of March 31, 2026). https://mjbizdaily.com/news/irs-wants-marijuana-mso-to-return-erroneous-280e-tax-refund-plus-interest/616104/
Discover Tailored Insurance Solutions
Unlock the potential of customized captive insurance designed specifically for your unique business needs.